Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Does Physician Education Influence Side Effect Management and Does it Increase Time on Treatment in the Absence of Progression ? A Phase 4 Open-label Trial With Regorafenib in Metastatic Colorectal Cancer

NCT02287025 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT02287025
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02287025 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Does Physician Education Influence Side Effect Management and Does it Increase Time on Treatment in the Absence of Progression ? A Phase 4 Open-label Trial With Regorafenib in Metastatic Colorectal Cancer
Lead sponsor
Bayer
Phase
Phase 4
Overall status
Terminated
Start date
November 11, 2014
Completion date
April 8, 2016
Enrollment
23 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

physician education